Lubiprostone in Children With Functional Constipation
A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation
Sponsor: Sucampo AG
Listed as NCT02042183, this PHASE3 trial focuses on Constipation - Functional and remains completed. Sponsored by Sucampo AG, it has been updated 11 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2020 — Aug 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2020 [monthly]
Completed PHASE3
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Apr 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sucampo AG
- Sucampo Pharma Americas, LLC
For direct contact, visit the study record on ClinicalTrials.gov .